Hot Up And Coming Stocks To Watch Right Now

The Home Depot, Inc. (NYSE:HD) is scheduled to report first quarter, 2014 sales and earnings before the open of the financial markets on Tuesday, May 20, 2014. On the same day, management will host a conference call at 9 a.m. ET to discuss the results.

Wall Street anticipates that home improvement retailer will earn $0.99 per share for the quarter, which is $0.16 more than last year's profit of $0.83 per share. iStock expects HD to top Wall Street's consensus number, the iEstimate is $1.00.

Revenue, like earnings, is expected to trend higher, increasing 4.3% year-over-year (YoY). The Home Depot's consensus revenue estimate for Q1 is $19.95 billion, more than last year's $19.12 billion.

[Related -May 20 Breakdown Trend Day Trading Update]

The Home Depot is the world's largest home improvement specialty retailer, with 2,263 retail stores in all 50 states, the District of Columbia, Puerto Rico, U.S. Virgin Islands, Guam, 10 Canadian provinces and Mexico.

Top 10 Medical Stocks To Watch Right Now: Bovie Medical Corporation (BVX)

Bovie Medical Corporation develops, manufactures, and markets medical products and devices with an emphasis on electrosurgical generators and electrosurgical disposables primarily in the United States. Its electrosurgery product line comprises desiccators, generators, electrodes, electrosurgical pencils, and various ancillary disposable products used in surgical procedures in gynecology, urology, plastic surgery, dermatology, veterinary, and other surgical markets for the cutting and coagulation of tissue. The company offers Aaron 900 and Aaron 940, which are high frequency desiccators designed primarily for dermatology and family practice physicians for removing small skin lesions and growths, as well as for office based coagulation. It also provides Aaron 950, a high frequency desiccator with cut capacity for outpatient surgical procedures; Aaron 1250U, a 120-watt multipurpose electrosurgery generator; and Aaron 2250/3250 and IDS 200/300/400 multipurpose digital electros urgery generators. In addition, the company offers ICON GI, ICON GP, and ICON VS specialty electrosurgical generators; Resistick II, a coating that is applied to stainless steel, which resists eschar during surgery; disposable laparoscopic instruments; and ICON GS (J-Plasma), a plasma system. Further, it provides battery operated cauteries used for sculpting woven grafts in bypass surgery, vasectomies, and evacuation of subungual hematoma, as well as for arresting bleeding in various types of surgeries; battery operated medical lights that act as specialty lighting instruments for use in ophthalmology as well as specialty lighting instruments for general surgery, hip replacement surgery, and for the placement of endotracheal tubes in emergency and surgical procedures; and nerve locator stimulators used for identifying motor nerves in hand and facial reconstructive surgery. Bovie Medical Corporation was founded in 1982 and is based in Melville, New York.

Advisors' Opinion:

• [By Andrew Stephan]

  The J-Plasma surgical technology from Bovie Medical Corporation (BVX) has recently begun to hit the market. Although it is anticipated sales will start out slowly due to the time involved in building and deploying a sales force specific to J-Plasma and in hospital capital equipment purchasing decisions, revenues from J-Plasma are expected to become very strong in 2014, leading to a correspondingly large upward move in the share price.

Hot Up And Coming Stocks To Watch Right Now: American Realty Capital Properties Inc (ARCP)

American Realty Capital Properties, Inc., incorporated on December 2, 2010, is a real estate investment trust (REIT). The Company owns and acquires single-tenant, freestanding commercial real estate primarily subject to medium-term net leases with credit quality tenants. The Company is externally managed by ARC Properties Advisors, LLC. In February 2013, it announced the closing of the transaction to acquire American Realty Capital Trust III, Inc. In March 2013, it announced that it purchased a TD Bank office building in Falmouth, Maine. In April 2013, it closed lease acquisitions, including nine properties located in four states plus Puerto Rico with approximately 200,000 total rentable square feet. In April 2013, it closed an additional single tenant net lease acquisitions, including six properties leased to four investment grade or credit-worthy tenants, including CVS, Family Dollar, Hy-Vee and Advance Auto. In November 2013, American Realty Capital Properties, Inc acquired CapLease, Inc. Effective January 3, 2014, American Realty Capital Properties Inc, , through its Thunder Acquisition LLC unit, acquired the entire share capital of American Realty Capital Trust IV Inc (ARCT).

As of December 31, 2012, rental revenues derived from investment grade tenants. As of December 31, 2012, the Company owned 146 properties, which consists of 2.4 million square feet and located in 26 states, excluding one vacant property classified as held for sale. The Company is holder of 95.9% of the interest in the ARC Properties Operating Partnership, L.P.

Advisors' Opinion:

• [By Sean Williams]

  What: Shares of CapLease (NYSE: LSE  ) , a REIT focused on investing in commercial real estate that is net-leased, soared as much as 23% after agreeing to be acquired by American Realty Capital (NASDAQ: ARCP  ) for $2.2 billion.

• [By Maria Armental and Tess Stynes var popups = dojo.query(".socialByline .popC"); ]

  American Realty Capital Properties Inc.(ARCP) said Wednesday it will sell its multi-tenant shopping center portfolio for $1.975 billion in cash to a Blackstone(BX) affiliate, instead of spinning off the division as it had previously announced. American Realty plans to use the proceeds to fund its Red Lobster sale-leaseback transaction. American Realty shares fell 2.3% to $12.60 premarket.

• [By Rich Duprey]

  Net-lease property REIT American Realty Capital Properties� (NASDAQ: ARCP  ) says that with Capital Lease Funding (NYSE: LSE  ) announcing the expiration of its 40-day "go shop" period and no other buyers being found, it plans to buy its rival sooner than originally intended.

Hot Up And Coming Stocks To Watch Right Now: Stemline Therapeutics Inc (STML)

Stemline Therapeutics, Inc. (Stemline), incorporated on August 8, 2003, is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics that target both cancer stem cells (CSCs) and tumor bulk. The Company is developing two clinical-stage product candidates, SL-401 and SL-701, for which it holds global marketing rights. The indication for SL-401, a biologic-drug conjugate, is acute myeloid leukemia (AML). The indications for SL-701, a synthetic peptide vaccine, are pediatric and adult brain cancer. It has a platform, StemScreen, for the discovery of CSC-targeted compounds, from which it has discovered or validated several of its clinical and preclinical product candidates. Stemline�� StemScreen consists of StemScreen-1 and StemScreen-2 for the identification of CSC-directed compounds.

SL-301 is a small molecule gamma-secretase inhibitor that inhibits Notch, a pathway expressed by CSCs and tumor bulk of multiple cancer types. SL-101 is a monoclonal antibody-based (mAb -based) compound that targets CD123 and has shown in vitro activity against certain hematologic cancers. SL-201 is a small molecule active against certain hematologic and solid tumor types. SL-601 is a mAb-based compound that targets a cell surface marker on bladder CSCs, which is also expressed on a variety of other solid tumor types. It has also in-licensed certain intellectual property directed to mAb-based therapeutics to validated oncology targets, including Glypican-3, Tie-1, CD133, Frizzled, Smoothened and Patched.

SL-401 - An IL-3R-Directed Compound Targeting Cancer Stem Cells and Tumor Bulk

SL-401 is a clinically active biologic-drug conjugate consisting of human interleukin-3 (IL-3) genetically linked to a truncated version of diphtheria toxin. SL-401 targets the IL-3 receptor (IL-3R), which is overexpressed on both the CSCs and tumor bulk of multiple hematologic cancers, including AML. SL-401 has demonstrated preclinical in vit! ro and in vivo activity against both leukemia blasts (which includes tumor bulk) and CSCs of a range of human leukemia cell lines and primary leukemia cells from patients.

SL-701

SL-701 is a clinically active synthetic peptide vaccine that targets several epitopes on CSCs and tumor bulk of brain cancer. In two completed Phase 1/2 clinical trials, SL-701 demonstrated single agent anti-tumor activity in pediatric patients with newly diagnosed brainstem glioma (BSG) and other high-grade gliomas (HGGs) and in adult patients with refractory or recurrent GBM, and other HGGs.

StemScreen-1

StemScreen-1 is a drug discovery platform designed to identify CSC-targeted compounds based on the isolation of CSCs and evaluation of CSC gene expression profiles. CSCs are isolated from primary tumor tissue or cell lines, and then subjected to gene expression analysis using a variety of technologies, including microarray. A control tissue, such as normal bone marrow is analyzed as a comparator against the gene expression profile of the isolated CSCs. These data are then interfaced with an information base of compounds and their mechanisms of action (that is which gene products and pathways they impact). It has utilized StemScreen-1 to discover a number of its preclinical drug candidates. These include SL-201, SL-301, and SL-601. In addition, SL-401 demonstrated activity against CSCs as determined by both an in vitro colony formation and in vivo animal implantation assay, thereby validating certain StemScreen-1 anti-CSC assays.

StemScreen-2

StemScreen-2 is a high throughput drug discovery platform it is developing to discover anti-CSC compounds. StemScreen-2 utilizes a cell-based assay that can track and follow CSCs in their natural state during high throughput screening. In particular, StemScreen-2 utilizes a CSC-specific promoter linked to a reporter as a method for identifying and following CSCs in their native environment of surrounding tumor b! ulk. In t! his way, StemScreen-2 enables the identification of compound hits, in a high throughput manner, with anti-CSC activity.

The Company competes with Boston Biomedical, Inc., Eclipse Therapeutics, Inc., OncoMed Pharmaceuticals, Inc., Verastem, Inc., Astellas Pharma US, Inc., Boehringer Ingelheim GmbH, Dainippon Sumitomo Pharma Co. Ltd., Geron Corp., GlaxoSmithKline plc, ImmunoCellular Therapeutics, Ltd, Macrogenics Inc., Amgen, Inc., Pfizer Inc., Roche Holding AG, Sanofi U.S. LLC., Cyclacel Pharmaceuticals, Inc., Sunesis Pharmaceuticals Inc., Clavis Pharma ASA, Ambit Biosciences Corporation, Celgene Corporation, Eisai Co. Ltd., Celator Pharmaceuticals, Inc., Merck & Co., Inc., Eisai Co., Inc., Roche Holding AG, Novartis AG and Celldex Therapeutics, Inc.

Advisors' Opinion:

• [By Jay Silverman]

  Some of the biggest leaders in that field, and there have been dozens in fields, if not more this year, such as Bluebird (BLUE) and Stemline Therapeutics (STML) and have all pulled back to significantly lower levels; even below, in Bluebird's case, the price that had actually opened up as an IPO, even though it's above its IPO price.

• [By David Zeiler]

  3. Stemline Therapeutics Inc. (Nasdaq: STML): This biotech develops drugs that target cancer stem cells and tumors. Stemline went public January 29 at $10 a share and rose just 11.78% on its first day. But STML has climbed steadily since, and currently trades at $37.46, up 274.6% from its IPO price.

• [By Keith Speights]

  Best-performing biotech IPO
  Stemline Therapeutics� (NASDAQ: STML  ) has only traded publicly this year, but what a year it's been. The stock's performance ranks Stemline as the best-performing biotech IPO so far in 2013. This week has been pretty good also, with shares moving up by 28%.

Hot Up And Coming Stocks To Watch Right Now: UMH Properties Inc.(UMH)

UMH Properties, Inc. (UMH) is a real estate investment trust. The firm engages in the ownership and operation of manufactured home communities. It leases manufactured home spaces to private manufactured home owners, as well as leases homes to residents. The firm invests in the real estate markets of New York, New Jersey, Pennsylvania, Ohio, and Tennessee. In addition, it invests in debt and equity securities of REITs. United Mobile Homes was incorporated in 1968. The company was formerly known as United Mobile Homes, Inc. UMH Properties is based in Freehold, New Jersey.

Advisors' Opinion:

• [By John Udovich]

  Trailer parks may have a bad reputation, but Yahoo! Finance�� Breakout segment was recently touting trailer parks as a hot new investment area���meaning its time for retail investors who don�� want to invest in physical parks to start taking a closer look at trailer park stocks Equity Lifestyle Properties, Inc (NYSE: ELS), Sun Communities Inc (NYSE: SUI) and UMH Properties, Inc (NYSE: UMH). According to the segment, roughly 6% of Americans lived in trailer homes as of 2012 with the�supply of designated trailer parks being quite low because no one wants one in their backyard. Anthony Effinger, the author of another article about trailer parks for Bloomberg, was quoted as saying:

Hot Up And Coming Stocks To Watch Right Now: PPL Corporation(PPL)

PPL Corporation, an energy and utility holding company, generates and sells electricity; and delivers natural gas to approximately 5.3 million utility customers primarily in the northeastern and northwestern U.S. The company operates in four segments: Kentucky Regulated, International Regulated, Pennsylvania Regulated, and Supply. The Kentucky Regulated segment engages in the generation, transmission, distribution, and sale of electricity; and the distribution and sale of natural gas to approximately 1.3 million customers in Kentucky, Virginia, and Tennessee. The International Regulated segment owns and operates electricity distribution businesses in the United Kingdom that deliver electricity to 7.7 million customers. The Pennsylvania Regulated segment delivers electricity to approximately 1.4 million customers in eastern and central Pennsylvania. The Supply segment owns and operates power plants to generate electricity using coal, uranium, natural gas, oil, and water res ources; markets and trades electricity and other purchased power to wholesale and retail markets; and acquires and develops domestic generation projects. It controls or owns a portfolio of generation assets of approximately 11,000 megawatts in Montana and Pennsylvania. As of December 31, 2010, the company?s distribution system included 649 substations with a capacity of 25 million kVA, 28,838 circuit miles of overhead lines, and 24,131 cable miles of underground conductors in the United Kingdom. It also operated 377 substations with a capacity of 31 million kVA, 33,122 circuit miles of overhead lines, and 7,368 cable miles of underground conductors in Pennsylvania. The company was founded in 1920 and is headquartered in Allentown, Pennsylvania.

Advisors' Opinion:

• [By Justin Loiseau]

  Hedging is common practice for any energy company, but Q1 earnings reports have already proven that this financial tactic can only absorb so much of increasingly volatile energy prices. Exelon (NYSE: EXC  ) took a one-time $235 million hit this quarter as a result of natural gas hedges gone wild, while PPL's (NYSE: PPL  ) bad bet helped knock around 20% off its first quarter EPS.

• [By Ben Levisohn]

  The S&P 500, meanwhile, was hit by big losses in Exelon (EXC), Goodyear Tire & Rubber (GT) and PPL Corp (PPL). Exelon dropped 3.8% to $35.75 after the utility announced a secondary offering, while Goodyear fell 2.8% to $26.17. PPL Corp declined 2.8% to $33.72 after announcing that it plans to spin off its Montana power plants.

• [By Justin Loiseau]

  Oil continues to prove less and less useful for generation as prices head higher, and hydro represents a calculated decision to focus its energy portfolio elsewhere. PPL (NYSE: PPL  ) announced this week that it has successfully completed a $209 million hydroelectric expansion project, increasing output 70% to 60 MW.

Hot Up And Coming Stocks To Watch Right Now: HSBC Holdings PLC (HBCYF)

HSBC Holdings plc (HSBC) is a global banking and financial services organizations. As of December 31, 2012, it provided a range of financial services to around 58 million customers through four global businesses: Retail Banking and Wealth Management, Commercial Banking, Global Banking and Markets, and Global Private Banking. In June 2012, the Company�� indirect wholly owned subsidiary, HSBC Iris Investments (Mauritius) Ltd, sold its 4.73% interest in Axis Bank Limited and 4.74% interest in Yes Bank Limited. In July 2012, its subsidiary, HSBC Europe (Netherlands B.V.), sold its 100% interest in HSBC Credit Zrt, to CentralFund Kockazati Tokealap. On March 31, 2013, Enstar Group Ltd�� subsidiary completed the acquisition from Household Insurance Group Holding Company of HSBC Insurance Company of Delaware and Household Life Insurance Company of Delaware, as well as its three subsidiary insurers. Advisors' Opinion:

• [By Mark Thompson]

  The Gold Fixing began as usual at 3 pm. Deutsche Bank (DB), HSBC (HBCYF), Scotiabank and Societe Generale (SCGLF) joined Barclays on a conference call.

Hot Up And Coming Stocks To Watch Right Now: Southern Cross Exploration NL (SXX)

Southern Cross Exploration NL is an Australia-based company engaged in the investment in the Bigrlyi Uranium Joint Venture, on which pre-development investigations and further drilling were carried out; exploration for gold and minerals, reviews of opportunities for participation in and/or acquisition of mineral exploration and mining ventures, and examination of projects in respect of different commodities, share investments, loans and other securities. The Bigrlyi project is located in the Ngalia Basin, northwest of Alice Springs, in the Northern Territory. The Company's interest in the Bigrlyi Uranium Joint Venture is one of its assets, in joint venture with two multi-billion dollar companies, CGNPC - via the Operator, Energy Metals Ltd (EME) - and Paladin Energy Ltd (PDN). Advisors' Opinion:

• [By idahansen]

  Due to the impact of The Great Recession, stocks in the agricultural sector such as Caterpillar (NYSE: CAT), The Mosiac Company (NYSE: MOS), and Potash of Saskatchewan (NYSE: POT) are trading well below highs. The exchange traded fund for the industry, DBA Power Shares, (NYSE: DBA), is down more than 17% for the last year. Despite this bearish trend, legendary investors such as Warren Buffett, George Soros, and Jim Rogers are very positive for the agriculture group. With the long term bullish outlook for the sector from the greatest investors in history, small cap stocks active in the fertilizer sector such as Sirius Minerals (LSE: SXX) and Americas Petrogas (TSX: BOE) are especially attractive.